{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:04:30Z","timestamp":1791428670804,"version":"4.3.3"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41573-024-01059-3","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T13:02:20Z","timestamp":1730725340000},"page":"40-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-7610","authenticated-orcid":false,"given":"Anneliene H.","family":"Jonker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7339-7175","authenticated-orcid":false,"given":"Elena-Alexandra","family":"Tataru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Graessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-2523","authenticated-orcid":false,"given":"David","family":"Dimmock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-9553","authenticated-orcid":false,"given":"Gareth","family":"Baynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-4357","authenticated-orcid":false,"given":"James","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Mitkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Iliach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika F.","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bateman-House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria Gerdina","family":"Pasmooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-7701","authenticated-orcid":false,"given":"Tim","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-7273","authenticated-orcid":false,"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Douville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Lapteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip John","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of The N-of-1 Task Force of the International Rare Diseases Research Consortium (IRDiRC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"1059_CR1","unstructured":"Rare Diseases International. Operational description of rare diseases. Rare Diseases International https:\/\/www.rarediseasesinternational.org\/fr\/definition-operationnelle-des-maladies-rares\/ (2023)."},{"key":"1059_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","volume":"19","author":"M Haendel","year":"2020","unstructured":"Haendel, M. et al. How many rare diseases are there? Nat. Rev. Drug. Discov. 19, 77\u201378 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrd.2017.246","volume":"17","author":"KM Boycott","year":"2018","unstructured":"Boycott, K. M. & Ardig\u00f3, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat. Rev. Drug. Discov. 17, 151\u2013152 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR4","doi-asserted-by":"publisher","first-page":"104698","DOI":"10.1016\/j.isci.2022.104698","volume":"25","author":"CIE Smith","year":"2022","unstructured":"Smith, C. I. E., Bergman, P. & Hagey, D. W. Estimating the number of diseases\u2014the concept of rare, ultra-rare, and hyper-rare. iScience 25, 104698 (2022).","journal-title":"iScience"},{"key":"1059_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12501","volume":"11","author":"HJS Dawkins","year":"2018","unstructured":"Dawkins, H. J. S. et al. Progress in rare diseases research 2010\u20132016: an IRDiRC Perspective. Clin. Transl. Sci. 11, 11\u201320 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"1059_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca, D. A., Amaral, I., Pinto, A. C. & Cotrim, M. D. Orphan drugs: major development challenges at the clinical stage. Drug. Discov. Today 24, 867\u2013872 (2019).","journal-title":"Drug. Discov. Today"},{"key":"1059_CR7","unstructured":"US Food and Drug Administration. Rare diseases: common issues in drug development guidance for industry. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry (2020)."},{"key":"1059_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"1059_CR9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub, V. et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 15, 882\u2013890 (2016).","journal-title":"Lancet Neurol."},{"key":"1059_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s13023-022-02529-w","volume":"17","author":"N Denton","year":"2022","unstructured":"Denton, N. et al. Sharing is caring: a call for a new era of rare disease research and development. Orphanet J. Rare Dis. 17, 389 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1059_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910486","volume":"11","author":"KM Boycott","year":"2019","unstructured":"Boycott, K. M., Lau, L. P., Cutillo, C. M. & Austin, C. P. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol. Med. 11, e10486 (2019).","journal-title":"EMBO Mol. Med."},{"key":"1059_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/gt.2017.29","volume":"24","author":"D Julkowska","year":"2017","unstructured":"Julkowska, D. et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 24, 562\u2013571 (2017).","journal-title":"Gene Ther."},{"key":"1059_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","volume":"11","author":"CP Austin","year":"2018","unstructured":"Austin, C. P. et al. Future of rare diseases research 2017\u20132027: an IRDiRC Perspective. Clin. Transl. Sci. 11, 21\u201327 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"1059_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02558-5","volume":"17","author":"B Dos Santos Vieira","year":"2022","unstructured":"Dos Santos Vieira, B. et al. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries. Orphanet J. Rare Dis. 17, 436 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1059_CR15","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","volume":"173","author":"W Sun","year":"2017","unstructured":"Sun, W., Zheng, W. & Simeonov, A. Drug discovery and development for rare genetic disorders. Am. J. Med. Genet. A 173, 2307\u20132322 (2017).","journal-title":"Am. J. Med. Genet. A"},{"key":"1059_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-020-00060-w","volume":"19","author":"A Hechtelt Jonker","year":"2020","unstructured":"Hechtelt Jonker, A. et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat. Rev. Drug. Discov. 19, 495\u2013496 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","volume":"19","author":"E Tambuyzer","year":"2020","unstructured":"Tambuyzer, E. et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug. Discov. 19, 93\u2013111 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR18","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/nat.2021.0035","volume":"32","author":"A Bateman-House","year":"2022","unstructured":"Bateman-House, A. & Kearns, L. Individualized therapeutics development for rare diseases: the current ethical landscape and policy responses. Nucleic Acid. Ther. 32, 111\u2013117 (2022).","journal-title":"Nucleic Acid. Ther."},{"key":"1059_CR20","doi-asserted-by":"crossref","unstructured":"Individualized ASO therapy for rare diseases. Commun. Med. 3, 27 (2023).","DOI":"10.1038\/s43856-023-00255-3"},{"key":"1059_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","volume":"96","author":"RC Griggs","year":"2009","unstructured":"Griggs, R. C. et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol. Genet. Metab. 96, 20\u201326 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"1059_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine, E. F., Adams, H. R. & Mink, J. W. Clinical trials in rare disease: challenges and opportunities. J. Child. Neurol. 28, 1142\u20131150 (2013).","journal-title":"J. Child. Neurol."},{"key":"1059_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9\u201321 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1059_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer, M. C., van Roon-Mom, W. & Aartsma-Rus, A. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun. Med. 4, 1\u201311 (2024).","journal-title":"Commun. Med."},{"key":"1059_CR25","doi-asserted-by":"crossref","unstructured":"Gene therapy for rare diseases. Nat. Genet. 22, 313\u2013314 (1999).","DOI":"10.1038\/11875"},{"key":"1059_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","volume":"21","author":"CJ Bashor","year":"2022","unstructured":"Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug. Discov. 21, 655\u2013675 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"1059_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).","journal-title":"Nat. Commun."},{"key":"1059_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li, T. et al. CRISPR\/Cas9 therapeutics: progress and prospects. Sig Transduct. Target. Ther. 8, 1\u201323 (2023).","journal-title":"Sig Transduct. Target. Ther."},{"key":"1059_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nn.4508","volume":"20","author":"DR Corey","year":"2017","unstructured":"Corey, D. R. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat. Neurosci. 20, 497\u2013499 (2017).","journal-title":"Nat. Neurosci."},{"key":"1059_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-019-00013-w","author":"C Arnold","year":"2019","unstructured":"Arnold, C. Tailored treatment for ALS poised to move ahead. Nat. Med. https:\/\/doi.org\/10.1038\/d41591-019-00013-w (2019).","journal-title":"Nat. Med."},{"key":"1059_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JND-200531","volume":"8","author":"M Cappella","year":"2021","unstructured":"Cappella, M., Pradat, P.-F., Querin, G. & Biferi, M. G. Beyond the traditional clinical trials for amyotrophic lateral sclerosis and the future impact of gene therapy. J. Neuromuscul. Dis. 8, 25\u201338 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"1059_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104\u2013116 (2022).","journal-title":"Nat. Med."},{"key":"1059_CR34","unstructured":"Mawr, B. Phase 3 trial of jacifusen for amyloid lateral sclerosis with fused-in-sarcoma mutation. Practical Neurology https:\/\/practicalneurology.com\/news\/phase-3-trial-of-jacifusen-for-amyloid-lateral-sclerosis-with-fused-in-sarcoma-mutation (2021)."},{"key":"1059_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06277-0","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. A framework for individualized splice-switching oligonucleotide therapy. Nature https:\/\/doi.org\/10.1038\/s41586-023-06277-0 (2023).","journal-title":"Nature"},{"key":"1059_CR36","unstructured":"Merlot, J. Ataxia teleangiectatica: Wie Eltern eine experimentelle Therapie entdeckten [German]. Der Spiegel (2023); https:\/\/www.spiegel.de\/wissenschaft\/medizin\/ataxia-teleangiectatica-wie-eltern-eine-experimentelle-therapie-entdeckten-a-f5c81ef8-0039-4a4e-960e-92c8ff8b5d0d."},{"key":"1059_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li, H. et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Sig Transduct. Target. Ther. 5, 1\u201323 (2020).","journal-title":"Sig Transduct. Target. Ther."},{"key":"1059_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Sig Transduct. Target. Ther. 6, 1\u201324 (2021).","journal-title":"Sig Transduct. Target. Ther."},{"key":"1059_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/d41573-024-00020-8","volume":"23","author":"PJ Brooks","year":"2024","unstructured":"Brooks, P. J. et al. The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases. Nat. Rev. Drug. Discov. 23, 157\u2013158 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR40","unstructured":"BGTC Consortium. Bespoke Gene Therapy Consortium (BGTC) regulatory playbook version 1.0. FNIH Foundation for the National Institutes of Health https:\/\/fnih.org\/wp-content\/uploads\/2024\/02\/BGTC-Regulatory-Playbook-preliminary-FINAL-FOR-RELEASE_20240205.pdf (2024)."},{"key":"1059_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41591-022-01687-5","volume":"28","author":"TW Yu","year":"2022","unstructured":"Yu, T. W. & Bodamer, O. A solid start for gene therapy in Tay\u2013Sachs disease. Nat. Med. 28, 236\u2013237 (2022).","journal-title":"Nat. Med."},{"key":"1059_CR42","unstructured":"Oleksiw, B. Battling SPG50 and changing the world. The Jackson Laboratory https:\/\/www.jax.org\/news-and-insights\/2022\/August\/battling-spg50-and-changing-the-world (2022)."},{"key":"1059_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR44","doi-asserted-by":"publisher","unstructured":"Kalland, M. E. et al. Advancing rare disease treatment: EMA\u2019s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene Ther 1\u201312 https:\/\/doi.org\/10.1038\/s41434-024-00446-0 (2024).","DOI":"10.1038\/s41434-024-00446-0"},{"key":"1059_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01720-2","volume":"22","author":"S Vivekanandhan","year":"2023","unstructured":"Vivekanandhan, S. et al. Immunotherapies in rare cancers. Mol. Cancer 22, 23 (2023).","journal-title":"Mol. Cancer"},{"key":"1059_CR46","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/ijms21093103","volume":"21","author":"R De Gioia","year":"2020","unstructured":"De Gioia, R. et al. Neural stem cell transplantation for neurodegenerative diseases. Int. J. Mol. Sci. 21, 3103 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1059_CR47","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti, A., Roncarolo, M. G. & Naldini, L. Gene therapy for ADA\u2010SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol. Med. 9, 737\u2013740 (2017).","journal-title":"EMBO Mol. Med."},{"key":"1059_CR48","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","volume":"114","author":"HB Gaspar","year":"2009","unstructured":"Gaspar, H. B. et al. How I treat ADA deficiency. Blood 114, 3524\u20133532 (2009).","journal-title":"Blood"},{"key":"1059_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR\u2013Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR\u2013Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR51","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.hoc.2022.05.002","volume":"36","author":"MH Porteus","year":"2022","unstructured":"Porteus, M. H., Pavel-Dinu, M. & Pai, S.-Y. A curative DNA code for hematopoietic defects: novel cell therapies for monogenic diseases of the blood and immune system. Hematol. Oncol. Clin. North. Am. 36, 647\u2013665 (2022).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"1059_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","volume":"42","author":"C Sheridan","year":"2023","unstructured":"Sheridan, C. The world\u2019s first CRISPR therapy is approved: who will receive it? Nat. Biotechnol. 42, 3\u20134 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1059_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309149","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst, H. J. et al. CRISPR\u2013Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2309149 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/d41586-023-03543-z","volume":"623","author":"M Naddaf","year":"2023","unstructured":"Naddaf, M. First trial of \u2018base editing\u2019 in humans lowers cholesterol\u2014but raises safety concerns. Nature 623, 671\u2013672 (2023).","journal-title":"Nature"},{"key":"1059_CR55","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/d41586-023-03797-7","volume":"624","author":"H Ledford","year":"2023","unstructured":"Ledford, H. CRISPR 2.0: a new wave of gene editors heads for clinical trials. Nature 624, 234\u2013235 (2023).","journal-title":"Nature"},{"key":"1059_CR56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161\u2013177 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"1059_CR57","unstructured":"National Institutes of Health. Somatic cell genome editing. NIH Common Fund https:\/\/commonfund.nih.gov\/editing."},{"key":"1059_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-021-03191-1","volume":"592","author":"K Saha","year":"2021","unstructured":"Saha, K. et al. The NIH somatic cell genome editing program. Nature 592, 195\u2013204 (2021).","journal-title":"Nature"},{"key":"1059_CR59","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","volume":"182","author":"W Wu","year":"2020","unstructured":"Wu, W. et al. Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy. Cell 182, 855\u2013871.e23 (2020).","journal-title":"Cell"},{"key":"1059_CR60","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"1059_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/mmr.2024.13171","volume":"29","author":"D Sun","year":"2024","unstructured":"Sun, D. et al. CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (review). Mol. Med. Rep. 29, 47 (2024).","journal-title":"Mol. Med. Rep."},{"key":"1059_CR62","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 139, 1794\u20131806 (2022).","journal-title":"Blood"},{"key":"1059_CR63","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR64","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"1059_CR65","doi-asserted-by":"publisher","unstructured":"Mitra, A. et al. From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049 (2023).","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"1059_CR66","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/25292","volume":"396","author":"C Lengauer","year":"1998","unstructured":"Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643\u2013649 (1998).","journal-title":"Nature"},{"key":"1059_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schr\u00f6rs, B., L\u00f6wer, M., T\u00fcreci, \u00d6. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug. Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR68","doi-asserted-by":"publisher","unstructured":"Fritah, H., Rovelli, R., Chiang, C. L.-L. & Kandalaft, L. E. The current clinical landscape of personalized cancer vaccines. Cancer Treat. Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102383 (2022).","DOI":"10.1016\/j.ctrv.2022.102383"},{"key":"1059_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","volume":"5","author":"A Corthay","year":"2014","unstructured":"Corthay, A. Does the immune system naturally protect against cancer? Front. Immunol. 5, 197 (2014).","journal-title":"Front. Immunol."},{"key":"1059_CR70","doi-asserted-by":"publisher","first-page":"16591","DOI":"10.3390\/ijms242316591","volume":"24","author":"L Secl\u00ec","year":"2023","unstructured":"Secl\u00ec, L. et al. Personalized cancer vaccines go viral: viral vectors in the era of personalized immunotherapy of cancer. Int. J. Mol. Sci. 24, 16591 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1059_CR71","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","volume":"22","author":"E Dolgin","year":"2023","unstructured":"Dolgin, E. Personalized cancer vaccines pass first major clinical test. Nat. Rev. Drug. Discov. 22, 607\u2013609 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1507-6","volume":"16","author":"LM Liau","year":"2018","unstructured":"Liau, L. M. et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med. 16, 142 (2018).","journal-title":"J. Transl. Med."},{"key":"1059_CR73","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026.e11 (2022).","journal-title":"Cancer Cell"},{"key":"1059_CR74","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Invest. 130, 5976\u20135988 (2020).","journal-title":"J. Clin. Invest."},{"key":"1059_CR75","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1059_CR76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"1059_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","volume":"74","author":"S Jia","year":"2023","unstructured":"Jia, S. & Taylor-Cousar, J. L. Cystic fibrosis modulator therapies. Annu. Rev. Med. 74, 413\u2013426 (2023).","journal-title":"Annu. Rev. Med."},{"key":"1059_CR78","doi-asserted-by":"publisher","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","volume":"27","author":"C Bareil","year":"2020","unstructured":"Bareil, C. & Bergougnoux, A. CFTR gene variants, epidemiology and molecular pathology. Arch. de. P\u00e9diatrie 27, eS8\u2013eS12 (2020).","journal-title":"Arch. de. P\u00e9diatrie"},{"key":"1059_CR79","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663\u20131672 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1059_CR80","unstructured":"US Food and Drug Administration. FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approved-use-kalydeco-treat-additional-mutations-cystic-fibrosis (2020)."},{"key":"1059_CR81","doi-asserted-by":"publisher","first-page":"210112","DOI":"10.1183\/20734735.0112-2021","volume":"17","author":"DH Tewkesbury","year":"2021","unstructured":"Tewkesbury, D. H., Robey, R. C. & Barry, P. J. Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe 17, 210112 (2021).","journal-title":"Breathe"},{"key":"1059_CR82","doi-asserted-by":"crossref","unstructured":"Awatade, N. T. et al. Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine. Front. Pharmacol. 9, 1429 (2018).","DOI":"10.3389\/fphar.2018.01429"},{"key":"1059_CR83","doi-asserted-by":"publisher","unstructured":"Sadras, I. et al. Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation. J. Cyst. Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2023.06.001 (2023).","DOI":"10.1016\/j.jcf.2023.06.001"},{"key":"1059_CR84","unstructured":"Genomics England. Pilot launched to support children with rare conditions to access personalized therapies. Genomics England https:\/\/www.genomicsengland.co.uk\/news\/pilot-launched-to-support-children-with-rare-conditions-to-access-personalised-therapies (2023)."},{"key":"1059_CR85","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41591-021-01657-3","volume":"28","author":"HL Rehm","year":"2022","unstructured":"Rehm, H. L. Time to make rare disease diagnosis accessible to all. Nat. Med. 28, 241\u2013242 (2022).","journal-title":"Nat. Med."},{"key":"1059_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01026-w","volume":"14","author":"S Marwaha","year":"2022","unstructured":"Marwaha, S., Knowles, J. W. & Ashley, E. A. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 14, 23 (2022).","journal-title":"Genome Med."},{"key":"1059_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027248","volume":"9","author":"A Jo","year":"2019","unstructured":"Jo, A. et al. Prevalence and practice for rare diseases in primary care: a national cross-sectional study in the USA. BMJ Open. 9, e027248 (2019).","journal-title":"BMJ Open."},{"key":"1059_CR88","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41576-019-0156-9","volume":"20","author":"G Saunders","year":"2019","unstructured":"Saunders, G. et al. Leveraging European infrastructures to access 1 million human genomes by 2022. Nat. Rev. Genet. 20, 693\u2013701 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"1059_CR89","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(23)02295-X","volume":"403","author":"C Turnbull","year":"2024","unstructured":"Turnbull, C. et al. Population screening requires robust evidence\u2014genomics is no exception. Lancet 403, 583\u2013586 (2024).","journal-title":"Lancet"},{"key":"1059_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-024-00410-2","volume":"9","author":"V Jobanputra","year":"2024","unstructured":"Jobanputra, V. et al. Advancing access to genome sequencing for rare genetic disorders: recent progress and call to action. npj Genom. Med. 9, 1\u20133 (2024).","journal-title":"npj Genom. Med."},{"key":"1059_CR91","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jval.2018.03.002","volume":"21","author":"S Auvin","year":"2018","unstructured":"Auvin, S., Irwin, J., Abi-Aad, P. & Battersby, A. The problem of rarity: estimation of prevalence in rare disease. Value Health 21, 501\u2013507 (2018).","journal-title":"Value Health"},{"key":"1059_CR92","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.3390\/ijerph20064732","volume":"20","author":"T Adachi","year":"2023","unstructured":"Adachi, T. et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int. J. Env. Res. Public. Health 20, 4732 (2023).","journal-title":"Int. J. Env. Res. Public. Health"},{"key":"1059_CR93","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","volume":"17","author":"M Shadid","year":"2021","unstructured":"Shadid, M., Badawi, M. & Abulrob, A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert. Opin. Drug. Metab. Toxicol. 17, 1281\u20131292 (2021).","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"1059_CR94","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013243","volume":"13","author":"SM Hammond","year":"2021","unstructured":"Hammond, S. M. et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol. Med. 13, e13243 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1059_CR95","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"CA Desjardins","year":"2022","unstructured":"Desjardins, C. A. et al. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res. 50, 11401\u201311414 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1059_CR96","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1261\/rna.079540.122","volume":"29","author":"A Aartsma-Rus","year":"2023","unstructured":"Aartsma-Rus, A. et al. Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA 29, 446\u2013454 (2023).","journal-title":"RNA"},{"key":"1059_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/am.am_82_23","volume":"20","author":"M Endrakanti","year":"2023","unstructured":"Endrakanti, M. & Gupta, N. Multidisciplinary Team for Genetic Disorders\u2014integration with clinicians and health-care professionals. Apollo Med. 20, 144 (2023).","journal-title":"Apollo Med."},{"key":"1059_CR98","doi-asserted-by":"publisher","unstructured":"Selby, P., Popescu, R., Lawler, M., Butcher, H. & Costa, A. The value and future developments of multidisciplinary team cancer care. Am. Soc. Clin. Oncol. Educ. Book. 332\u2013340 https:\/\/doi.org\/10.1200\/EDBK_236857 (2019).","DOI":"10.1200\/EDBK_236857"},{"key":"1059_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1072-y","volume":"14","author":"S Auvin","year":"2019","unstructured":"Auvin, S. et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J. Rare Dis. 14, 91 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"1059_CR100","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-021-01380-z","volume":"27","author":"A Aartsma-Rus","year":"2021","unstructured":"Aartsma-Rus, A. \u2018N of 1\u2019 therapies need a better model. Nat. Med. 27, 939 (2021).","journal-title":"Nat. Med."},{"key":"1059_CR101","unstructured":"Eurofins. What is the difference between GLP, GCP, and GMP laboratory testing regulations? eurofins https:\/\/www.eurofinsus.com\/food-testing\/resources\/good-laboratory-practices-vs-good-manufacturing-practices-whats-the-difference\/ (2024)."},{"key":"1059_CR102","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/stcltm\/szac046","volume":"11","author":"L Lopez-Navas","year":"2022","unstructured":"Lopez-Navas, L., Torrents, S., S\u00e1nchez-Pernaute, R. & Vives, J. Compliance in non-clinical development of cell-, gene-, and tissue-based medicines: good practice for better therapies. Stem Cell Transl. Med. 11, 805\u2013813 (2022).","journal-title":"Stem Cell Transl. Med."},{"key":"1059_CR103","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s00415-023-11868-y","volume":"270","author":"J Seemann","year":"2023","unstructured":"Seemann, J., Trasch\u00fctz, A., Ilg, W. & Synofzik, M. 4-Aminopyridine improves real-life gait performance in SCA27B on a single-subject level: a prospective N-of-1 treatment experience. J. Neurol. 270, 5629\u20135634 (2023).","journal-title":"J. Neurol."},{"key":"1059_CR104","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13023-020-01475-9","volume":"15","author":"E Indelicato","year":"2020","unstructured":"Indelicato, E. et al. Onset features and time to diagnosis in Friedreich\u2019s ataxia. Orphanet J. Rare Dis. 15, 198 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1059_CR105","unstructured":"Newton, W. Drug development for ultra-rare diseases: what happens when N\u2009=\u20091? Clinical Trials Arena https:\/\/www.clinicaltrialsarena.com\/features\/drug-development-for-ultra-rare-diseases-what-happens-when-n1\/ (2022)."},{"key":"1059_CR106","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41591-024-03071-x","volume":"30","author":"JMY Pian","year":"2024","unstructured":"Pian, J. M. Y. et al. How to pay for individualized genetic medicines. Nat. Med. 30, 1816\u20131818 (2024).","journal-title":"Nat. Med."},{"key":"1059_CR107","unstructured":"Rand, P. S.5002\u2014117th Congress (2021\u20132022): FDA Modernization Act 2.0. Congress.gov https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002 (2022)."},{"key":"1059_CR108","unstructured":"European Medicines Agency. EMA implements new measures to minimise animal testing during medicines development. EMA https:\/\/www.ema.europa.eu\/en\/news\/ema-implements-new-measures-minimise-animal-testing-during-medicines-development (2021)."},{"key":"1059_CR109","doi-asserted-by":"crossref","unstructured":"Phares, S., Trusheim, M., Emond, S. K. & Pearson, S. D. Managing the challenges of paying for gene therapy: strategies for market action and policy reform. ICER https:\/\/icer.org\/wp-content\/uploads\/2024\/04\/Managing-the-Challenges-of-Paying-for-Gene-Therapy-_-ICER-NEWDIGS-White-Paper-2024_final.pdf (2024).","DOI":"10.57264\/cer-2024-0118"},{"key":"1059_CR110","unstructured":"Univ. of Oxford. Chancellor announces support for Rare Therapies Launch Pad. Department of Paediatrics https:\/\/www.paediatrics.ox.ac.uk\/news\/chancellor-announces-support-for-rare-therapies-launch-pad (2024)."},{"key":"1059_CR111","unstructured":"European Union\u2014Expert Panel on effective ways of investing in Health. Innovative payment models for high-cost innovative medicines. European Commission https:\/\/health.ec.europa.eu\/system\/files\/2019-11\/opinion_innovative_medicines_en_0.pdf (2018)."},{"key":"1059_CR112","unstructured":"Lindner, L. & Lorenzoni, L. OECD Health Working Papers. Innovative providers\u2019 payment models for promoting value-based health systems: Start. small, prove value, scale up. OECD https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2023\/04\/innovative-providers-payment-models-for-promoting-value-based-health-systems_5884ddf4\/627fe490-en.pdf (2023)."},{"key":"1059_CR113","doi-asserted-by":"publisher","first-page":"pages307","DOI":"10.1038\/s41586-024-07800-7","volume":"634","author":"M Kliegman","year":"2024","unstructured":"Kliegman, M. et al. A roadmap for affordable genetic medicines. Nature 634, pages307\u2013314 (2024).","journal-title":"Nature"},{"key":"1059_CR114","unstructured":"NEJM Catalyst. What is pay for performance in healthcare? NEJM Catalyst (1 March 2018); https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.18.0245."},{"key":"1059_CR115","unstructured":"International Rare Diseases Research Consortium. N-of-1 Task Force education resources. IRDiRC https:\/\/irdirc.org\/wp-content\/uploads\/2023\/12\/N-of-1-Education-Resources-1-1.pdf (2024)."},{"key":"1059_CR116","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41587-021-00945-0","volume":"39","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T. A call to arms against ultra-rare diseases. Nat. Biotechnol. 39, 671\u2013677 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1059_CR117","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/d41573-021-00193-6","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell, K. \u2018Bespoke Gene Therapy Consortium\u2019 sets out to enable gene therapies for ultra-rare diseases. Nat. Rev. Drug. Discov. 20, 886\u2013887 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1059_CR118","unstructured":"Bespoke Gene Therapy Consortium. Accelerating Medicines Partnership (AMP). National Institutes of Health (NIH) https:\/\/www.nih.gov\/research-training\/accelerating-medicines-partnership-amp\/bespoke-gene-therapy-consortium (2021)."},{"key":"1059_CR119","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41591-023-02208-8","volume":"29","author":"T Fox","year":"2023","unstructured":"Fox, T. et al. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat. Med. 29, 518\u2013519 (2023).","journal-title":"Nat. Med."},{"key":"1059_CR120","unstructured":"US Food and Drug Administration. Investigational New Drug (IND) application. FDA https:\/\/www.fda.gov\/drugs\/types-applications\/investigational-new-drug-ind-application (2022)."},{"key":"1059_CR121","unstructured":"US Food and Drug Administration. Expanded access. FDA https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-access (2022)."},{"key":"1059_CR122","unstructured":"US Food and Drug Administration. Facilitating end-to-end development of individualized therapeutics. FDA https:\/\/www.fda.gov\/media\/134856\/download (2020)."},{"key":"1059_CR123","unstructured":"US Food and Drug Administration. Scientific challenges and opportunities to advance the development of individualized cellular and gene therapies; request for information. Regulations.gov https:\/\/www.regulations.gov\/document\/FDA-2023-N-3742-0001 (2023)."},{"key":"1059_CR124","unstructured":"US Food and Drug Administration. IND submissions for individualized antisense oligonucleotide drug products for severely debilitating or life-threatening diseases: clinical recommendations. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-life (2022)."},{"key":"1059_CR125","unstructured":"Rep. Eshoo, A. G. H.R.7667\u2014117th Congress (2021\u20132022): Food and drug amendments of 2022. Congress.gov https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/7667 (2022)."},{"key":"1059_CR126","unstructured":"US Food and Drug Administration. Platform Technology Designation Program for Drug Development. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/platform-technology-designation-program-drug-development (2024)."},{"key":"1059_CR127","unstructured":"European Commission. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. OJEC 311, 67\u2013128 (2001)."},{"key":"1059_CR128","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/nat.2021.0039","volume":"32","author":"M Synofzik","year":"2022","unstructured":"Synofzik, M. et al. Preparing N-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives. Nucleic Acid. Ther. 32, 83\u201394 (2022).","journal-title":"Nucleic Acid. Ther."},{"key":"1059_CR129","unstructured":"Autralian Government Medical Services Advisory Committee. Public summary document: Application No. 1519.1\u2014tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). MSAC.gov http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/content\/A2B10F9A03293BC8CA2583CF001C7A4D\/$File\/1519.1%20Final%20updated%20PSD%20Nov%2019_redacted.pdf (2019)."},{"key":"1059_CR130","unstructured":"Health Canada. Improving the regulatory review of drugs and devices. Government of Canada https:\/\/www.canada.ca\/en\/health-canada\/corporate\/transparency\/regulatory-transparency-and-openness\/improving-review-drugs-devices.html (2017)."},{"key":"1059_CR131","unstructured":"Health Canada. Health and biosciences: targeted regulatory review\u2014regulatory roadmap. Government of Canada https:\/\/www.canada.ca\/en\/health-canada\/corporate\/about-health-canada\/legislation-guidelines\/acts-regulations\/targeted-regulatory-reviews\/health-biosciences-sector-regulatory-review\/roadmap.html (2020)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01059-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:03:16Z","timestamp":1790118196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01059-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1038\/s41573-024-01059-3","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"19 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.-R. is an unpaid board member of the Dutch Centre for RNA Therapeutics and an unpaid board member of the\n                      N\n                      \u2009=\u20091 Collaborative (N1C). A.B.-H. is an uncompensated volunteer for the n-Lorem Foundation\u2019s Access to Treatment committee. A.J. has received speaking fees from Vertex Biopharmaceuticals. D.D. is an employee of Creyon Bio. H.G. is a Member of the Board of Directors of the N1C. D.O.\u2019C. is involved in the Rare Therapies Launch Pad (RTLP) as representative for the ABPI, a non-financial interaction. J.Da. is co-founder of Nucleome Therapeutics and provides consultancy to the company; and has intellectual property licensed to BEAM therapeutics, receives revenue from this licence and holds personal shares. M.S. has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and Solaxa, all unrelated to the present manuscript; and is an unpaid board member of the N1C. R.H. is CEO and founder of Cure Rare Disease; CEO and founder of Myofinity Biosciences; and Consultant for Neuromuscular Disease Foundation. T.Y. has received research support for an\n                      N\n                      \u2009=\u20091 trial in ataxia telangiectasia from EveryONE Medicines, and is named as an inventor on three patents pertaining to antisense oligonucleotide (ASO) treatments for transposon-associated diseases (WO2019055460A1), ataxia telangiectasia (US20230174979A1) and progranulin (US11359199B2); has received scientific consulting fees as pertains to ASO therapies from GeneTx, RegUp and Servier Pharmaceuticals; serves as an unpaid Board Member for the N1C, the Oligonucleotide Therapeutics Society and the Society for RNA Therapeutics; and serves as an unpaid scientific adviser to several rare disease foundations. A.H.-J., E.-A.T, G.B., S.M., O.I., E.F.A., A.M.G.P., J.D., L.L. and\u00a0P.J.B. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}